Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.33 |
| ▸ | PDE1A | P54750 | 4/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26795202 | 0.78 | PDE1C (0.42) | GRM4PDE1CPDE1APDE1BCYP1A2 | |
| SCHEMBL25908338 | 0.78 | TIPARP (0.34) | FLT3 | |
| SCHEMBL26795358 | 0.78 | PDE1C (0.38) | GRM4PDE1CPDE1APDE1BCYP1A2 | |
| SCHEMBL26795283 | 0.75 | GRM4 (0.34) | GRM4PDE1CPDE1APDE1BKIT | |
| SCHEMBL25322327 | 0.74 | TIPARP (0.42) | GRM4KITFLT3 | |
| SCHEMBL30550762 | 0.74 | TIPARP (0.42) | GRM4KITFLT3 | |
| SCHEMBL26795404 | 0.73 | KDM1A (0.34) | GRM4PDE1CPDE1APDE1BCYP1A2 | |
| SCHEMBL26795337 | 0.72 | PDE4A (0.35) | GRM4PDE1CPDE1APDE1BCYP1A2 | |
| SCHEMBL26804099 | 0.72 | TIPARP (0.38) | GRM4PDE1CPDE1APDE1BCYP1A2 | |
| SCHEMBL26804054 | 0.72 | PDE1C (0.36) | GRM4PDE1CPDE1APDE1BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | GRM4 4760/4885PDE1C 3801/4885PDE1A 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.